Remove 2025 Remove Drug Development Remove Drugs
article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

article thumbnail

Future-proofing drug development with GenAI

Drug Target Review

Given macro healthcare influences (eg, economic uncertainty, environmental changes) and the numerous available treatments for major diseases, drug developers may need to reassess their therapeutic strategies. This has led drug developers to unintentionally limit their potential within chosen therapeutic spaces.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Altasciences at ARVO 2025: An Eye on the Future of Ophthalmic Drug Development by Gretchen Green

Alta Sciences

Showcasing Breakthroughs in Ocular Safety and Translational Models We were especially honored to have Dr. Makori and Dr. Iwabe present a symposium titled Ocular Toxicology Studies of New Drug Modalities: An Approach to Reduce Animal Use. 1] [link] ; This blog was originally published in June 2025. conference locations.

article thumbnail

Altasciences At CPHI Americas 2025

Alta Sciences

Altasciences At CPHI Americas 2025 pmjackson Thu, 07/03/2025 - 13:41 In the ever-changing drug development world, staying agile is essential to enabling more informed decisions, faster. It’s a challenge that affects a large percentage of new drug candidates—one we’re passionate about helping to solve.

article thumbnail

Leveraging Machine Learning to Accelerate Drug Development

Fierce BioTech

Leveraging Machine Learning to Accelerate Drug Development Discover how CDMOs are using machine learning to speed up drug development, cut costs, and improve quality. mcottam Mon, 06/23/2025 - 14:54 Discover how CDMOs are using machine learning to speed up drug development, cut costs, and improve quality.

article thumbnail

Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development

Alta Sciences

Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development pmjackson Wed, 02/19/2025 - 21:30 The unique physicochemical properties of oligonucleotides require the use of specialized bioanalytical approaches, with key considerations including selectivity and specificity, sensitivity, stability, and matrix effects.

article thumbnail

Enhancing Your Experience: What to Expect From Us in 2025

PPD

Unlocking new levels of value with expanded offerings We are launching more dynamic and integrated service offerings that leverage the very latest automation and integrations to accelerate your unique drug development journey in new and different ways. Contact your business development representative to learn more.